with DNA-reactive antiretroviral drugs. A prospective study was conducted of 26 HIV-infected men who provided samples before treatment and at multiple times after beginning treatment, to investigate effects of antiretrovirals on lymphocyte and sperm chromosomes and semen quality. Several antiretroviral regimens, all including a nucleoside component, were used. Lymphocyte metaphase analysis and sperm fluorescence in situ hybridization were used for cytogenetic studies. Semen analyses included conventional parameters (volume, concentration, viability, motility, and morphology). No significant effects on cytogenetic parameters, semen volume, or sperm concentration were detected. However, there were significant improvements in sperm motility for men with study entry CD4 cell counts 1200 cells/mm 3 , sperm morphology for men with entry CD4 cell counts р200 cells/mm 3 , and the percentage of viable sperm in both groups. These findings suggest that nucleoside-containing antiretrovirals administered via recommended protocols do not induce chromosomal changes in lymphocytes or sperm but may produce improvements in semen quality.
.
Antiretroviral drugs administered to study subjects and specific treatment regimens represented in this study and no. of subjects receiving each regimem Specific a One patient switched from d4T, 3TC, lopinavir, and ritonavir to Zdv, 3TC, lopinavir, and ritonavir; both treatments are indicated, and total no. of patients equals 27, rather than 26. fectious Disease Clinics at Duke University Medical Center Hospital and University of North Carolina Hospital at Chapel Hill from July 1997 through December 1998. Study subjects were otherwise healthy patients diagnosed with HIV infection and were about to start antiretroviral therapy with a regimen that included at least 1 nucleoside analogue. Furthermore, subjects must not have received nucleoside analogue therapy in the past year, must not have undergone a vasectomy, and may not have had any history of sperm or reproductive problems. They needed to be able to read and understand English and be willing to donate blood and semen samples repeatedly over the 12-week research period. Sixty men met these criteria and were asked to participate. Of these, 26 (43%) agreed, and 34 (57%) refused. The major reasons given for refusal to participate were embarrassment regarding semen donation, transportation difficulties, and/or scheduling problems. The 26 men who agreed to participate did not differ significantly from nonparticipants for age, race, or range of virus load and CD4 cell counts reported by the recruiting clinics during the recruitment period. Selected demographic and clinical characteristics of the study subjects are shown in table 1. None of the men had known occupational exposures to potential mutagens or chemicals that might alter their sperm. Various antiretroviral treatment therapies were administered (table 2) . However, all study subjects received Zdv or lamivudine (3TC), or both, as a component of their therapy. Selfreported adherence to prescribed drug therapy averaged 95.3% (SD, 2.1%). Drug levels were measured in a subset of subjects [20] providing further evidence of adherence to prescribed treatment at time of semen collection. Drug toxicities were closely monitored, and no research subjects discontinued nucleoside analogue therapy because of severe drug toxicity during the study. One subject substituted Zdv for stavudine (d4T) several weeks into treatment because of side effects.
Study Design
The longitudinal study design included repeated collection of biologic, clinical, and questionnaire data over 12 weeks. Sampling times coincided with routine clinic visits as much as possible. There were 4 sampling times: baseline before initiation of drug therapy and at 4, 6-8, and 12 weeks after initiation of drug therapy. These specific time points were chosen to target sensitive periods of spermatogenesis. The 6-8 week time period was chosen to assess effects during meiosis, and the 12-week (or greater) exposure period permitted assessment of stem cell effects. In addition, the 4-week point for peripheral blood and semen sampling was chosen to assess potential effects from the typical treatment duration of postexposure prophylactic treatment that would be administered for occupational exposures [4] .
Questionnaires, Semen, and Blood Collection
Before antiretroviral drug treatment was initiated, study managers administered standardized questionnaires and reviewed medical records to obtain data that included age, race, occupation, therapeutic drug history (both for treatment of HIV infection and for unrelated conditions), CD4 cell count, and information on current or recent illnesses. In addition, before the start of treatment and at each subsequent visit, a self-administered questionnaire was used to collect data on lifestyle factors that might affect semen quality, such as recent caffeine consumption (e.g., sodas, coffee, and/or tea), cigarette or pipe use, alcohol consumption, and exposure to high temperatures via sauna or hot tub.
For the lymphocyte cytogenetic assays, whole blood samples were drawn into an 8-mL sodium heparin green top Vacutainer tube during the clinic visit and were transported at room temperature via same-day courier service to LabCorp (Research Triangle Park, NC) for lymphocyte culturing and slide preparation. Semen samples were obtained by masturbation, either in the clinic or at the subject's home, and were delivered to the andrology laboratory at either the University of North Carolina or Duke University for routine semen analysis [21] . An abstinence interval of at least 2 days was recommended before collection of the study sample [21] , although not all men adhered to this recommendation. Because of the requested minimum 2-day abstinence period between semen sample collections, the need for subjects not to delay the start of their medications, as well as the need to avoid requesting multiple additional clinic visits that might affect participation rates, we constrained our sampling to a single semen specimen per time point of interest. Delivery of specimens to the andrology laboratory for motility analysis within 2 h of collection was specified but was not possible in all cases.
Laboratory Analyses
Lymphocyte cytogenetic assays. Lymphocyte culturing and slide preparation were done by means of published cytogenetic techniques [22, 23] . A 48-h culturing period was used. In most cases, 600 wellspread metaphases from each blood sample were scored for frequency of chromosomal aberrations. Categories of aberrations scored included chromatid and chromosome breaks, double minutes, triradials, quadriradials, dicentrics, rings, complex rearrangements, cells with 110 aberrations, pulverized cells, and pulverized chromosomes. Gaps were scored and recorded but were not included in the analysis of cells with chromosomal aberrance. The mitotic index was determined from at least 1000 cells. Genetic Research (Chapel Hill, NC) scored the lymphocyte spreads.
Sperm aneuploidy and chromosome breakage assays. Sperm fluorescence in situ hybridization (FISH) analyses for aneuploidy were performed on thawed aliquots of semen, according to the method described by Robbins et al. [24] . Direct-labeled, high-intensity fluorophore a satellite probes for chromosomes X (labeled with SpectrumGreen) and 18 (labeled with SpectrumAqua), as well as satellite III DNA for the Y chromosome (labeled with Spectrum Orange), were used. Probes were purchased from Vysis. About 10,000 sperm cells/sample (range, 9951-10,056 sperm cells/sample) were scored for aneuploidy. Sperm cytogenetic analyses for chromosome breakage followed the chromatin preparation protocol, as described by Robbins et al. [24] . Hybridization was adapted for sperm from the method for buccal cells described by Rupa and Eastmond [25] . The methods differed as follows: probe mixture contained 7.7 mL of hybrizol hybridization buffer (Oncore), 1 mL of direct fluorescein isothiocyanate-labeled a satellite probe targeting a small centromeric region of chromosome 1 (Vysis), and 1.3 mL of direct Cy3-labeled probe targeting adjacent classical satellite II region within the chromosome 1 heterochromatin (provided by D. A. Eastmond, University of California, Riverside). Posthybridization washes were in 50% formamide-2ϫ standard saline citrate (SSC) at 45ЊC for 10 min, which was followed by 1ϫ SSC at 45ЊC for 10 min. Slides were counterstained with 0.025 mg of 4 ,6-diamidino-2-phenylindole (DAPI) in VectaShield mounting medium. A total of 3000 sperm cells/sample was scored for chromosome 1 breakage.
Conventional semen analysis. Semen samples were evaluated for semen volume, sperm concentration (by means of hemocytometer), percentage of motile sperm, and percentage of viable sperm (eosin B dye exclusion). Air-dried semen smears were fixed in 95% ethanol and were mailed to Fertility Solutions (Cleveland), where they were stained with Papanicolau stain and were subjected to morphology assessment by using World Health Organization criteria [21] and strict criteria [26] . After scoring 200 sperm cells/ sample, the percentage of morphologically normal sperm cells in each sample was calculated for each method. The remaining semen was aliquoted into cryovials and was frozen without cryopreservative at Ϫ70ЊC. Samples were later shipped by overnight delivery on dry ice to University of California, Los Angeles, for sperm cytogenetic analyses.
Statistical Analyses
Lymphocyte cytogenetics.
Analysis of variance procedures were used to assess the significance of differences in chromosomal aberration frequencies among sample time groups, differences among recruitment sites, and subject-to-subject variability. Pairwise comparisons were made by the Dunnett test. We applied the variance stabilizing arc sine transformation to these percentages before statistical analysis. In addition, regression analyses were carried out to assess possible linear or quadratic trends in response as a function of time. Within individual subjects, time-related changes in lymphocyte chromosomal aberration frequencies were assessed by Cochran-Armitage trend tests. Significance was set at . P ! .05 With this study design and scoring 600 cells/sample, there was 90% power to detect a 3-fold change in aberration frequency per subject over time.
Sperm aneuploidy and sperm chromosome breakage. Analysis of variance procedures were used to assess the significance of differences in sample time groups, differences among recruitment sites, and subject-to-subject variability. The variance-stabilizing arc sine transformation was used in these analyses. Pairwise comparisons among the different sample times were made by the Dunnett test. With this study design and significance set at , power calculations in-P ! .05 dicated at least a 75% probability of detecting a doubling for any one of the pretreatment values. For most of the variables, including total aneuploidy and total breakage, the power to detect a doubling was 195%.
Conventional semen analyses.
As with the lymphocyte and sperm data, semen end points were analyzed for treatment-related changes. In addition, the semen data were further analyzed to determine whether any observed changes were correlated with disease stage of the study subjects at the time of enrollment. Disease stage was classified by CD4 cell counts as follows: early disease (1200 cells/mm 3 ) or later disease (р200 cells/mm 3 ). The statistical package used for the conventional semen analysis was S-PLUS version 5.1 (Mathsoft).
To simplify the analyses and to reduce the number of degrees of freedom of the tests for differences in the semen end points, all during-treatment groups were combined into 1 group. This combination was motivated by the relatively few men under study, by differences among subjects in the timing of the different visits after treatment initiation, and by the presence of missing observations. Since the during-treatment groups were combined before any analyses, there is no inflation of the type I error rate. Because of the longitudinal study design, we expect good power to detect moderate-sized differences in end points, such as morphology, which do not exhibit much variability within a subject. However, our NOTE. For each subject, data are pretreatment values followed by 2 sequential during-treatment values (about 4 and 12 weeks after initiation of therapy). Additional samples obtained for 4 subjects were after at least 1 year of continuous therapy; the data did not confirm the shorter-term trends, except for subject A. Subjects A and B had significant decreases, whereas subjects C-F had significant increases. Significance was determined by Cochran Armitage trend test.
a Trend also significant ( ) with 1-year follow-up data. P ! .05 b No further samples were obtained from this subject.
power to detect treatment effects on volume and concentration, which are highly variable, is low.
Analysis of variance methods, after log transformation, were used to assess changes in semen volume and concentration. Logistic regression analyses were used to assess changes in the proportion of motile, viable, and morphologically normal sperm. Variability among subjects was accounted for by including the subject as a blocking factor in each model. Since human sperm motility and viability have been reported to decline with time after ejaculation and would be expected to decrease by as much as 25% in 5 h [27] , the statistical analysis for motility and viability was controlled for sample aging. We included indicators of !2, 2-4, and 14 h in the relevant models. Analyses of volume and concentration were adjusted for abstinence intervals of !2 versus у2 days.
Results
Lymphocyte cytogenetic end points. A total of 26 men donated blood for the lymphocyte cytogenetic evaluation before treatment and ∼4 and 12 weeks after the initiation of treatment. Most study subjects could schedule blood draws at the intervals designated in the study protocol; however, allowances were made for subjects to continue their participation in the study, despite occasional scheduling difficulties. Analysis of pooled data for all 26 men showed no statistically significant association between chromosomal aberration frequencies and length of treatment (  ; table 3 ). None of the mean values of P p .174 the treatment groups differed significantly from the pretreatment value, and there were no significant trends when time was used as an independent variable. In addition to treatment time, aberration frequencies also were analyzed with respect to source clinic (Duke University vs. University of North Carolina at Chapel Hill) and treatment regimen (presence or absence of Zdv and effects associated with any of the 10 individual drugs in the 8 treatment regimens used for this group of 26 men). No associations among any of these factors and chromosomal aberration frequencies were identified. Chromosomal aberration frequencies also were measured in 16 of the original 26 study subjects after at least 1 year of continuous antiretroviral therapy. The mean frequency at 1 year was slightly lower than the mean pretreatment value, but the difference was not statistically significant (table 3) .
Because study subjects served as their own controls by providing a pretreatment blood sample, chromosomal aberration frequencies could be monitored throughout the course of the study for each subject. No biologically relevant changes in lymphocyte chromosomal aberration frequencies were observed for any of the 26 subjects. None of the values obtained during treatment exceeded the upper range established by the pretreatment measurements, and all values were within the normal range (mean, 1.98; range, 0-6) previously reported for healthy people [28, 29] . Suggestions of treatment-related changes in aberrations were noted for 6 study subjects during the first 12 weeks of treatment (4 increases and 2 decreases) but these were generally not confirmed in long-term follow-up measurements taken after at least 1 year of antiretroviral drug therapy ( Fifteen men had adequate semen sample remaining for the sperm aneuploidy assay, and 13 had adequate sample for the additional sperm chromosome breakage assay after conventional semen analyses were complete. Sperm-FISH was used to detect and measure aneuploidy involving chromosomes X, Y, 1, 18, and diploidy XY18-18 and breakage in chromosome 1. Hybridization efficiency for both the aneuploidy and breakage assays exceeded 99.98%. No statistically significant treatmentrelated effects were found in the sperm cytogenetic assays across the sampling times (table 5) , except XY18-18 at midstudy ( ). In addition, the ratio of X:Y-bearing sperm did not P ! .05 differ from the expected 50:50 ratio at pretreatment or at any follow-up treatment visit.
Semen analysis end points. Twenty men donated semen samples at the initial (drug naive) visit and at least 1 follow-up visit. The semen analyses were based on these 20 study subjects, 9 with a CD4 cell count !200 cells/mm 3 on entry into the study (categorized as late disease) and 11 with a CD4 cell count 1200 cells/ mm 3 at study entry (categorized as early disease). The mean values for the percentages of sperm that were motile, viable, and morphologically normal and for the semen volume and concentration are presented in table 6. When more than 1 during-treatment sample was available for a given man, the values for these samples were pooled before calculating the means across men.
On the basis of linear regression analyses that accounted for abstinence interval (!2 days) and intersubject variability, there were no significant treatment-related differences in semen volume or concentration ( and , respectively). On the P p .79 P p .77 basis of logistic regression analyses that were stratified by patients and that accounted for variable time from semen donation until semen analysis (!2, 2-4, and 14 h), there were highly significant ( ) differences between pre-and during-treatment semen P ! .01 samples in 3 areas: the percentage of motile sperm from men with early disease; the percentage of viable sperm, regardless of CD4 cell count; and the percentage of sperm with normal morphology from men with late disease (figure 1). These differences all reflect improvements in semen quality with treatment.
There were no significant treatment-related differences in either the percentage of motile sperm from men with late disease or the percentage of sperm with normal morphology from men with early disease. In general, treatment-related differences in sperm viability and morphology were greater for samples from men with late disease, whereas differences in sperm motility were greater for men with early disease. However, even without stratification based on CD4 cell count, there were significant treatment-related improvements in sperm motility, viability, and morphology ( , , and , respectively). P ! .01 P ! .01 P p .015 We also tested separately for treatment-related differences within morphologic categories (table 6) by using logistic regression with patient as a blocking factor. There were significant treatment-related differences in the percentage of sperm with tapered heads ( ), amorphous shape ( ), and tail ab-P p .04 P p .01 normality (
). The percentages of sperm with tapered heads P ! .01 and with amorphous shape decreased with treatment, whereas the percentage with tail abnormalities increased with treatment.
Discussion
Although advances in antiretroviral therapy have brought many benefits, the long-term effects of these therapies are not known and could be of considerable importance. For example, protease inhibitors are now recognized to have a variety of important long-term metabolic effects [30] [31] [32] [33] . The majority of patients with HIV receive at least 1 nucleoside reverse-transcriptase inhibitor as a component of drug therapy [4] . Because nucleoside reverse-transcriptase inhibitors are designed specifically to incorporate into DNA [3] , it is reasonable to ask whether these drugs can affect chromosomal and genetic integrity.
Early studies of humans treated with high doses of the nucleoside reverse-transcriptase inhibitor Zdv demonstrated cytogenetic damage. A 16-fold increase in chromosomal aberrations in blood lymphocytes from 7 patients with AIDS treated with Zdv (1200 mg/day for 1-7 months), compared with that in blood lymphocytes from 4 patients with AIDS without exposure to Zdv or other nucleoside analogues, was reported by Shafik et al. [12] . Increased micronucleus frequencies in human B and T cells, telomere shortening, and large gene deletion mutations were found in in vitro studies by using cell lines treated with Zdv [34] [35] [36] [37] . Multidosing animal studies also have found cytogenetic effects in the form of micronucleus induction and telomere shortening [11, [13] [14] [15] [16] 38] .
In our study, adverse effects of nucleoside reverse-transcriptase inhibitors on lymphocyte chromosome aberrations could not be demonstrated by using aggregate data across all men. On an individual basis, 6 men showed statistically significant changes (4 increases and 2 decreases) in aberration frequency related to treatment. However, no values exceeded the highest value defined by the pretreatment frequencies (range of aberrant cells in pretreatment samples, 0.3%-4.5%), no values fell outside the range reported previously for healthy people [28, 29] , and the direction of observed changes was inconsistent among the 6 subjects. This strongly suggests that the individual findings are not biologically significant or treatment related. Indeed, follow-up blood samples provided by some of these subjects at 11 year showed a return toward pretreatment aberration frequencies, and tests for trends recalculated to include the long-term follow-up values were generally nonsignificant (table 4) . Virus load values and CD4 cell levels indicated good response to antiretroviral therapy for each of these 6 patients, and mitotic indices measured in the stimulated lymphocyte cultures were considerably improved at the time of long term follow-up. Thus, blood parameters are consistent with good response to treatment. Regarding germ cell cytogenetic damage induced by exposure to nucleoside reverse-transcriptase inhibitors, no human sperm aneuploidy or chromosome breakage studies have been published. However, the US National Toxicology Program (NTP) conducted tests for induction of chromosome damage by both Zdv and d4T in male mouse germ cells by using the dominant lethal test. After acute treatment by intraperitoneal injection, neither Zdv nor d4T induced such damage (authors' unpublished data).
In the current study, we did not detect significant treatmentassociated cytogenetic changes in sperm aneuploidy for chromosomes X, Y, 1, and 18 or breakage for chromosome 1. A finding of diploid sperm at midstudy (indicated by XY18-18;
) is biologically unexpected, since meiotic errors (e.g., P ! .05 XY18 aneuploidy) would be more likely. The finding of a statistically significant result is consistent with chance alone because of the multiple sperm cytogenetic outcomes evaluated. The finding of diploid sperm midstudy resolved by the final collection time point.
In previous studies, sperm aneuploidy was useful for detecting cytogenetic damage associated with chemotherapeutic, occupational, environmental, and lifestyle exposures [39] [40] [41] [42] . Most of the previous studies used cross-sectional designs. However, longitudinal sampling would be expected to provide more power to detect induced effects. We sampled longitudinally at time points expected to capture stem cell and meiotic effects and scored 10,000 sperm cells/sample. Aggregate frequencies for sperm aneuploidy for the men in the current study fell within the ranges reported for unexposed cohorts in other published research studies for all abnormalities, except XY18 [24, 39, 40] . On the basis of ∼10,000 sperm cells scored per man, the mean value for XY18 aneuploidy was 23.9 (SD, 13.9; range, 7-61). This is twice the mean value reported for healthy men [24, 39, 41] . Nuovo et al. [43] found that viral DNA, in the testes of men infected with HIV had localized primarily to spermatogonia and spermatocytes and, to a lesser extent, was associated only with postmeiotic spermatids. Because XY18 aneuploidy represents a meiosis I error, the high values detected in our study are of interest and deserve further investigation.
In the current study, we adapted the tandem-labeling technique to detect chromosome breakage in sperm cells of the study subjects. Tandem labeling has proven useful in detecting chromosome breakage in irradiated human lymphocytes in vitro and in buccal mucosal cells in vivo [25, 44, 45] . No baseline chromosome breakage frequencies for sperm by using tandem labeling have been published; however, our results for sperm (∼1 breakage event per chromosome 1 per 1000 sperm cells scored) fall within the range reported for buccal cells and lym- phocytes [24, 44] . No differences in breakage frequencies were detected among sampling times. Thus, we did not detect an effect of nucleoside reverse-transcriptase inhibitors on sperm aneuploidy or breakage over the 4-month study period.
The majority of recent semen studies done with men on antiretroviral therapy have looked at effects of treatment on semen infectivity for HIV [20, [46] [47] [48] [49] . However, several investigators have examined the effects of antiretroviral therapy on semen quality [20, [50] [51] [52] [53] . Krieger et al. [50] found no significant effects of Zdv on semen parameters in HIV-infected men on antiretroviral therapy for an average of 4 months (range, 1-11 months). Crittenden et al. [51] found no significant effects in men sampled before and as much as 12 months after starting Zdv therapy (doses of 600-1200 mg/day). In a study conducted by Politch et al. [52] , HIV-1 infected men with a CD4 cell count 1200 cells/mm 3 had semen parameters consistent with those of fertility, whereas men with a CD4 count !200 cells/mm 3 initially had lower counts that subsequently improved with Zdv treatment (100-200 mg every 4 h). Muller et al. [53] examined differences in semen quality between 250 HIV-seropositive men and 38 healthy fertile control subjects in a cross-sectional design. A subgroup of men receiving antiretroviral drugs was examined for treatment-related semen effects; only small changes in volume and pH were found. By use of computeraided motility and morphology assessment, they observed correlations between CD4 cell count and semen quality, noting that men with fewer CD4 cells had significantly decreased motility and poorer strict criteria morphology; sperm counts were not affected in these men.
The NTP evaluated effects of Zdv on male reproductive parameters in mice and rats [18] . At the highest dose of 1000 mg/ kg, modest decreases were observed in mouse testis and rat epididymal weights; epididymal sperm density was reduced in both rats and mice. None of these changes were considered to be significant. Additional NTP tests evaluated the potential reproductive effects of Zdv in CD1 mice by using the Reproductive Assessment by Continuous Breeding protocol, as described by Chapin and Sloane [17] . After twice daily oral administration of 50-200 mg of Zdv/kg of body weight for up to 90 days, dose-related decreases for all treatment groups in the F0 generation were observed for several end points, including the number of pups/litter; sperm motility, velocity, linearity, and density; and spermatid head counts. At the highest dose in the F1 generation, slight decreases were noted in the number of pups per litter (authors' unpublished data).
In the current study, we found that antiretroviral therapy led to improved sperm motility, viability, and morphology. The improvement in sperm motility was most pronounced among subjects with early disease (CD4 cell count at study entry, 1200 cells/mm 3 ). Improvement in viability and morphology was most pronounced among subjects with later disease (CD4 cell count at study entry, !200 cells/mm 3 ). Nucleoside antiretroviral drugs appear to concentrate in semen and may gain access to sperm cells during their formation [47] . These results suggest that antiretroviral therapy could lead to improved fertility in men with HIV infection.
There are limitations to the current study. First, the observational nature of the study did not permit control over the nucleoside antiretroviral therapies used. Thus, a wide variety of drug regimens were studied in a relatively small group of men. An uninfected control group was not enrolled because of concerns about previous animal and human study data showing adverse effects of nucleoside analogues on cytogenetic end points. The inclusion of an untreated HIV-infected group was initially considered. However, no study subjects opted to defer drug therapy; therefore, an untreated HIV-infected group was not enrolled. Adherence to drug therapy might have been overestimated, as this information was self-reported; actual drug levels were measured only in a subset of subjects at the time of semen donation. Finally, the time period for follow-up was chosen to maximize detection of cytogenetic effects in blood and semen, including stem cell effects, and to span a complete cycle of spermatogenesis. However, chronic long-term effects could be missed by this sampling scheme.
In conclusion, this longitudinal study provided us with the opportunity to examine sperm and lymphocyte cytogenetic end points plus semen quality parameters in men receiving antiretroviral therapy. We failed to detect any significant chromosomal aberrations either in lymphocytes or sperm cells that would suggest increased risk for neoplasms or cytogenetic problems in offspring of patients with HIV receiving antiretroviral therapy. Further longitudinal studies and clinical studies that include men, women, and their children will be required to confirm these results. The use of antiretroviral therapies has led to dramatic improvement in health and survival of patients with HIV. Along with increased life expectancy, people with HIV infection are pursuing options for conceiving healthy offspring. For our study cohort, improvements in semen quality were noted for sperm motility, viability, and morphology. Given the current need for a lifelong therapy with nucleoside analogues, these results can be viewed as reassuring.
